Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025.

Under plans to extend the company’s cash runway into 2026, Sana said it has halted development of its CD19-directed allogeneic CAR T-cell therapy, dubbed SC291, in cancer and will instead focus ...

Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships ...

Sana Biotechnology (NASDAQ:SANA) reported encouraging early data from a Phase 1 study for its CD19-directed allogeneic CAR T therapy called SC291 in the treatment of chronic lymphocytic leukemia ...

Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships ...

SC291 is a hypoimmune (HIP)-modified CD19-directed allogeneic CAR T therapy. It is currently being evaluated in the company’s GLEAM trial, targeting B-cell mediated autoimmune diseases ...

Prioritize clinical and preclinical development on type 1 diabetes (UP421 and SC451), B-cell mediated autoimmune diseases (SC291), refractory B-cell malignancies (SC262), and the fusogen platform ...

[Click here for information about joining the class action] On November 4, 2024, Sana issued a press release announcing that it "will suspend development of both SC291 in oncology and of SC379 ...

GLEAM trial for SC291 in B-cell mediated autoimmune diseases, and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect data from these studies in 2024 and/or 2025 Announced ...

The Seattle-based firm will focus on its SC291 and UP421 programs for B-cell mediated autoimmune diseases and type 1 diabetes, respectively, with multiple data readouts expected in the next two years.